论文部分内容阅读
目的：观察金尔伦对急性脑梗死患者血浆β—内啡肽（β—ＥＰ）的影响及临床疗效。方法：４９例急性脑梗死患者根据入院的先后顺序随机进入金尔伦组（２５例）和常规治疗组（２４例）。金尔伦组在常规治疗的基础上加金尔伦２ｍｇ静脉滴注，每日一次，连续１４ｄ。两组在用药前后均测定血浆β—ＥＰ含量，并观察其肢体功能的改变。结果：金尔伦组、常规治疗组和健康对照组治疗前血浆β—ＥＰ含量分别为（７３１．５±２０．４）ｐｇ／Ｌ、（７２８．０±２１．８）ｐｇ／Ｌ和（５３７．８±２１．７）ｐｇ／Ｌ、治疗后分别为（５６３．７±２４．２）ｐｇ／Ｌ和（６３１．４±２３．６）ｐｇ／Ｌ。此外，临床症状和神经功能缺损的改善，金尔伦组均优于常规治疗组（Ｐ＜０．０１）。结论金尔伦可拮抗急性脑梗死患者β—ＥＰ的生物效应，改善临床症状。
Objective: To observe the effect of Huron on plasma beta-endorphin (β-EP) in patients with acute cerebral infarction and its clinical efficacy. Methods: Forty-nine patients with acute cerebral infarction were randomly divided into Hurun group (n = 25) and conventional treatment group (n = 24) according to the order of admission. The group of Huron was treated with intravenous infusion of 2mg per day on the basis of routine treatment, once a day for 14 days. Both groups were measured before and after treatment of plasma β-EP content, and observe the changes in limb function. Results: The plasma levels of β-EP before treatment in Jinren group, routine treatment group and healthy control group were (731.5 ± 20.4) pg / L, (728.0 ± 21.8) pg / L and 537.8 ± 21.7 pg / L, respectively, and were 563.7 ± 24.2 pg / L and 631.4 ± 23.6 pg / L, respectively. In addition, the improvement of clinical symptoms and neurological deficits was better in the Huron group than in the conventional treatment group (P <0.01). Conclusion Huron can antagonize the biological effects of β-EP in patients with acute cerebral infarction and improve the clinical symptoms.